Arvind Meena, Deepak Kumar, Rajasri Bhattacharyya and Dibyajyoti Banerjee*
Department of Experimental Medicine and Biotechnology, Postgraduate Institute of Medical Education and Research, Chandigarh, India
*Corresponding Author: Dibyajyoti Banerjee, Department of Experimental Medicine and Biotechnology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Received: August 01, 2018; Published: August 21, 2018
Citation: Dibyajyoti Banerjee., et al. “Aspirin to Prevent CAD: Not Beyond Trials”. Acta Scientific Medical Sciences 2.6 (2018).
The world is facing an epidemic of coronary artery disease (CAD) . There is a considerable current interest in molecular research to unravel the mysteries behind it. However, the scenario is far from the control.
The CAD patients commonly use aspirin. It is believed that this drug in small dose will inhibit the increment of thrombus formation. Several clinical trials are also in favour of such a strategy, and currently, most textbooks approve the medicine for the purpose [2,3].
Copyright: © 2018 Dibyajyoti Banerjee., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.